RXRX
Recursion·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Negative Gross Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RXRX
Recursion Pharmaceuticals, Inc.
A clinical-stage biotechnology company that develops technologies to enable drug discovery
Biological Technology
11/04/2013
04/16/2021
NASDAQ Stock Exchange
800
12-31
Common stock
41 S Rio Grande Street, Salt Lake City, UT 84101
--
Recursion Pharmaceuticals, Inc., was originally established on November 4, 2013 and is incorporated in Delaware. The company is a leading clinical-stage TechBio company that decodes biology to industrialize drug discovery. At the heart of the company's mission is the Recursive Operating System (OS), a platform built across multiple technologies that enables the company to map and navigate trillions of biological, chemical and patient-centric relationships in over 50 petabytes of proprietary data. The company frames this integration of physical and digital components as an iterative loop in which large-scale "wet lab" biological, chemical and patient-centric experimental data are organized by "dry lab" computing tools in order to identify, validate and translate therapeutic insights.
Earnings Call
Q1/2025
Estimate EPS-0.52
Actual EPS-0.5
Estimate Revenue18.08M
Actual Revenue14.75M
Recursion Pharmaceuticals Q1 2025: Navigating Contradictions in Burn Rate, Pipeline Strategy, and Regulatory Adaptation
May 06,2025 07:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.35
Actual EPS-0.41
Estimate Revenue15.38M
Actual Revenue19.22M
Recursion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Innovation
Aug 05,2025 02:57
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
RXRX has released its 2025 Q3 earnings. EPS was reported at -0.36, versus the expected -0.38, beating expectations. The chart below visualizes how RXRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RXRX has released its 2025 Q3 earnings report, with revenue of 5.17M, reflecting a YoY change of -80.16%, and net profit of -162.25M, showing a YoY change of -69.29%. The Sankey diagram below clearly presents RXRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
